A recent study published in The New England Journal of Medicine demonstrated that once-daily brensocatib, a dipeptidyl peptidase 1 inhibitor, reduced pulmonary exacerbations by 21% and slowed lung function decline over 52 weeks in patients with bronchiectasis. The study reported significant reductions in exacerbation rates and lung function decline with brensocatib compared to placebo.

Source: The New England Journal of Medicine